Labcorp (LH) UBS Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
UBS Global Healthcare Conference summary
11 Nov, 2026Third-quarter performance and central lab
Revenue grew 7%, adjusted EPS increased 14.5%, and margin expanded 60 bps; guidance midpoints rose by $65M for revenue and $0.18 for adjusted EPS.
Central lab revenue grew 11.3% organically at constant currency in Q3, primarily on underlying demand; some customer study starts were pulled forward.
Central lab grew ~8% organically at constant currency through Q3 YTD; FY2026 outlook was raised to high-single-digit organic constant-currency revenue growth.
Book-to-bill was 1.13 for Q3 and 1.10 on a trailing-12-month basis; central lab bookings remained strong and ED bookings improved.
Management cited strong growth, margin expansion, raised guidance and momentum as support for confidence in the growth outlook heading into 2027.
Diagnostics and specialty testing
Q3 Diagnostics organic revenue grew 4.4%, including 3.1% volume and 1.3% price mix; organic volume growth was ~2% for the first three quarters.
Esoteric tests rose from 38% of Diagnostics revenue in Q1 2024 to ~42% in Q2 2026; tests per accession have increased slightly but consistently each quarter since the post-COVID rebound.
Specialty testing sales were ~$2B; 2022–2025 CAGR ranged from 10% in women’s health to 15% in oncology and autoimmune, and 25% in neurology, with core growth strong excluding acquisitions.
FY2026 Diagnostics revenue growth outlook was 5.9% at the midpoint; organic growth is expected to lead, with volume slightly ahead of price mix.
For 2027–2029, organic revenue growth outlook is 3.5%–5.5% total and 2.5%–4.5% in Diagnostics; inorganic contribution is expected at 1.5%–2.5%.
PAMA and operating outlook
If the current preliminary PAMA design takes effect in 2027, the estimated impact is ~$125M in revenue and AOI before mitigation, tied to traditional Medicare and Medicaid; this is slightly less than 1% of enterprise revenue.
Most commercial contracts are decoupled from the CMS fee schedule; some third-party contracts could have manageable knock-on effects.
Annual LaunchPad savings target rises from $100M–$125M to $125M–$150M starting in 2027, with AI, robotics and other technology improvements as key levers.
Margin expansion outlook remains 75–150 bps by end-2029; PAMA in its current design would make 2027 margin growth more challenging, with multiple levers available to manage the impact.
RESULTS Act was described as the preferred long-term industry solution; CBO scoring was pending, while efforts to pursue legislative reform would continue if PAMA proceeds.
Latest events from Labcorp
- Q3 growth lifted FY26 guidance, while a $125M PAMA impact looms in 2027.LH
Q3 2026 - Reaffirmed strong growth outlook, driven by specialty testing, tech, and strategic acquisitions.LH
Morgan Stanley 24th Annual Global Healthcare Conference - Specialty diagnostics, innovation, and disciplined capital deployment drive strong growth.LH
Investor Day 2026 - Q2 2026 revenue rose 5.8% to $3.73B, with adjusted EPS up 14.9% and raised full-year guidance.LH
Q2 2026 - Q1 momentum, specialty testing, and AI-driven innovation fuel growth and strategic expansion.LH
Jefferies Global Healthcare Conference 2026 - All agenda items passed, with management highlighting financial strength and addressing supply chain risks.LH
AGM 2026 - Q1 2026 delivered 5.8% revenue growth, higher margins, and raised guidance for the full year.LH
Q1 2026 - 2025 saw record revenues, board refreshment, and strong ESG and pay-for-performance alignment.LH
Proxy filing - Q2 2025 revenue up 9.5% to $3.53B, with double-digit growth and raised full-year guidance.LH
Q2 2025